Subscribe to STAT+ and access exclusive benefits this month
When you're a STAT+ subscriber, you get to enjoy perks like discounts on our STAT Reports and events, free access to premium data tools like our CRISPR TRACKR, as well as in-depth daily coverage and analysis of the life sciences.
SUBSCRIBE
Date: October 18 - 19, 2023
Location: Boston, MA / Virtual
Health care is supposed to be a system – from the early funding of new ideas to patients receiving the treatment they need. We'll take a look at the entire system, incorporating the perspectives of innovators, those on the medical front lines, and patients. And we'll look for solutions. Take advantage of early bird pricing and save over 40% when you register before July 16.
STAT+ subscribers can save an extra 20% on early bird tickets.
LEARN MORE
Date: September 5 - 7, 2023 from 1 – 3 p.m. ET each day
Location: Virtual
This virtual summit will bring together big name executives, global policymakers and patient advocates for deep discussions on the state of health care, from what's next in genetics and gene therapy to the future of cancer research.
STAT + Subscribers can attend for free!
LEARN MORE
Date: July 18, 2023 at 1:00 pm ET
Location: Virtual
Will the arrival of biosimilar versions of Humira finally prove the case that biosimilars can deliver on big health care savings? STAT's Ed Silverman asks this, and much more, of a panel of experts. Dive in and discuss what to watch in the months ahead.
REGISTER
Medicine's plunge into the digital world has made vast changes in the culture of health care and in how medicine itself is practiced. Digital tools now aid in clinical decision-making, warn of an impending illness, and can even render a diagnosis. However, the integration of technology into health care workflows has its challenges. Download your guide to this new age in health care now.
Download this e-book for free.
Download
Dates: July 16, 17, 19
Sign up for your free guide to the Alzheimers Association International Conference. STAT'll be there, on the conference floor, sharing updates and insights you won't want to miss.
Sign up
ALEX HOGAN/STAT
In February 2022, Diego Miralles, then-CEO of a buzzy new biotech called Laronde, gathered his employees in the company's shiny new Somerville, Mass., headquarters to relay some unsettling news. An internal investigation had uncovered a "bad assay" and poor note-taking in some of the core research being conducted at the company, Miralles told Laronde's roughly 130 staffers. The incident was serious, he said, and the company needed to learn from it.
Though couched in careful language, his meaning was clear: There was a problem with some of Laronde's key preclinical data.
Read More
STAT+ Reads
Check out our recent top stories:
- 'It's beyond unethical': Opaque conflicts of interest permeate prescription drug benefits by Bob Herman
- Francis deSouza's tenure at Illumina is a lesson in how not to handle CEO succession by Matthew Herper
- Hospitals want to buy doctors' happiness with Nuance's AI scribe. What they're paying varies by Brittany Trang
READ MORE
No comments